What top creators are saying about Abbott Laboratories(ABT)
Multinational medical devices and health care company.
6 AI-extracted insights from 5 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Not enough scored insights about Abbott Laboratories in the last 30 days yet.
Top creators covering Abbott Laboratories (ABT)
The 5 sources with the most insights about Abbott Laboratories on Kazuha.
Latest insights about Abbott Laboratories (ABT)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Saturday, May 9, 2026
Diagnostics winner; sees revenue spikes from testing scales before vaccine rollout.
Thursday, November 20, 2025
The stock was down after announcing its acquisition of Exact Sciences, indicating a negative market reaction to the deal.
Wednesday, October 8, 2025
The combination of corporate lobbying for the 'Circuit Act' and recent stock purchases by multiple bipartisan members of Congress presents a potentially bullish case for the stock.
Friday, August 15, 2025
Removed from the GRNY ETF portfolio during its August 2025 rebalance.
Tuesday, August 5, 2025
The FDA commissioner's positive mention of wearable glucometers is a bullish signal for Abbott, which makes the FreeStyle Libre, and suggests an expanding market beyond just diabetes management.
Monday, July 14, 2025
Bullish view due to strong growth in its diabetes (Freestyle) and medical devices businesses, which are described as being 'on fire' and offsetting weakness in other segments.
Saturday, May 9, 2026
Diagnostics winner; sees revenue spikes from testing scales before vaccine rollout.
Thursday, November 20, 2025
The stock was down after announcing its acquisition of Exact Sciences, indicating a negative market reaction to the deal.
Wednesday, October 8, 2025
The combination of corporate lobbying for the 'Circuit Act' and recent stock purchases by multiple bipartisan members of Congress presents a potentially bullish case for the stock.
Friday, August 15, 2025
Removed from the GRNY ETF portfolio during its August 2025 rebalance.
Tuesday, August 5, 2025
The FDA commissioner's positive mention of wearable glucometers is a bullish signal for Abbott, which makes the FreeStyle Libre, and suggests an expanding market beyond just diabetes management.
Monday, July 14, 2025
Bullish view due to strong growth in its diabetes (Freestyle) and medical devices businesses, which are described as being 'on fire' and offsetting weakness in other segments.
Discussed alongside Abbott Laboratories (ABT)
Other assets that creators frequently mention in the same content as Abbott Laboratories.
Frequently asked
Which podcasters and creators cover Abbott Laboratories (ABT) the most?
The most active sources covering Abbott Laboratories (ABT) on Kazuha are @realmartinshkreli, amitisinvesting, @cryptobantergroup, @quiverquant, The Wall Street Journal & Spotify Studios. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Abbott Laboratories (ABT) are on Kazuha?
Kazuha has indexed 6 AI-extracted insights about Abbott Laboratories (ABT) from 5 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Abbott Laboratories (ABT)?
Creators covering Abbott Laboratories (ABT) most frequently also discuss BTC, BHVN, NVDA, MAR, IONQ. See the "Discussed alongside" section above for full asset pages.